X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ALKEM LABORATORIES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ALKEM LABORATORIES PFIZER/
ALKEM LABORATORIES
 
P/E (TTM) x 34.1 - - View Chart
P/BV x 4.8 6.6 72.7% View Chart
Dividend Yield % 0.7 0.7 108.1%  

Financials

 PFIZER   ALKEM LABORATORIES
EQUITY SHARE DATA
    PFIZER
Mar-18
ALKEM LABORATORIES
Mar-16
PFIZER/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,3651,589 148.8%   
Low Rs1,6251,232 131.9%   
Sales per share (Unadj.) Rs430.3417.5 103.1%  
Earnings per share (Unadj.) Rs78.756.3 139.8%  
Cash flow per share (Unadj.) Rs93.264.7 144.0%  
Dividends per share (Unadj.) Rs20.0012.70 157.5%  
Dividend yield (eoy) %1.00.9 111.3%  
Book value per share (Unadj.) Rs586.5292.9 200.2%  
Shares outstanding (eoy) m45.75119.57 38.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.63.4 137.2%   
Avg P/E ratio x25.325.1 101.2%  
P/CF ratio (eoy) x21.421.8 98.2%  
Price / Book Value ratio x3.44.8 70.6%  
Dividend payout %25.422.6 112.6%   
Avg Mkt Cap Rs m91,271168,653 54.1%   
No. of employees `0002.6NA-   
Total wages/salary Rs m3,1439,171 34.3%   
Avg. sales/employee Rs Th7,484.8NM-  
Avg. wages/employee Rs Th1,195.0NM-  
Avg. net profit/employee Rs Th1,369.1NM-  
INCOME DATA
Net Sales Rs m19,68549,915 39.4%  
Other income Rs m1,1431,645 69.5%   
Total revenues Rs m20,82851,561 40.4%   
Gross profit Rs m5,0038,482 59.0%  
Depreciation Rs m6631,006 65.9%   
Interest Rs m4671 0.6%   
Profit before tax Rs m5,4798,451 64.8%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8781,606 117.0%   
Profit after tax Rs m3,6016,731 53.5%  
Gross profit margin %25.417.0 149.6%  
Effective tax rate %34.319.0 180.4%   
Net profit margin %18.313.5 135.6%  
BALANCE SHEET DATA
Current assets Rs m24,16727,062 89.3%   
Current liabilities Rs m9,54415,324 62.3%   
Net working cap to sales %74.323.5 315.9%  
Current ratio x2.51.8 143.4%  
Inventory Days Days5567 82.8%  
Debtors Days Days2941 69.5%  
Net fixed assets Rs m9,51412,610 75.4%   
Share capital Rs m458239 191.3%   
"Free" reserves Rs m26,37534,490 76.5%   
Net worth Rs m26,83235,027 76.6%   
Long term debt Rs m251,212 2.1%   
Total assets Rs m36,90054,387 67.8%  
Interest coverage x1,305.513.6 9,598.1%   
Debt to equity ratio x00 2.7%  
Sales to assets ratio x0.50.9 58.1%   
Return on assets %9.813.6 71.8%  
Return on equity %13.419.2 69.8%  
Return on capital %20.424.9 82.1%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m226,563 0.3%   
Fx outflow Rs m1,4893,012 49.4%   
Net fx Rs m-1,4663,552 -41.3%   
CASH FLOW
From Operations Rs m3,3187,259 45.7%  
From Investments Rs m-2,3831,864 -127.8%  
From Financial Activity Rs m-1,104-9,273 11.9%  
Net Cashflow Rs m-169-150 112.3%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 33.1 22.7%  
FIIs % 4.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 0.0 -  
Shareholders   85,207 68,381 124.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  UNICHEM LAB  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 16, 2018 (Close)

TRACK PFIZER

PFIZER - STRIDES PHARMA SCIENCE COMPARISON

COMPARE PFIZER WITH

MARKET STATS